# Endometrial and Cervical Cancer Treatments

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers encompasses a wide range of research on gynecologic oncology, including advancements in the understanding and treatment of endometrial carcinoma and cervical cancer. Topics covered include molecular classification, radiation therapy techniques such as brachytherapy, the role of sentinel lymph node biopsy, the efficacy of chemoradiotherapy, advancements in robotic surgery, and survival analysis. The cluster also includes discussions on clinical practice guidelines for the management of gynecologic cancers. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10668 |
| Works | 405 |

## Topic papers all

Showing 15 of 405.

- [Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis](https://scholariq.org/papers/estimates-of-incidence-and-mortality-of-cervical-cancer-in-2018-a-worldwide/)
- [Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer](https://scholariq.org/papers/concurrent-cisplatin-based-radiotherapy-and-chemotherapy-for-locally-advanced/)
- [Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix](https://scholariq.org/papers/concurrent-chemotherapy-and-pelvic-radiation-therapy-compared-with-pelvic/)
- [ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma](https://scholariq.org/papers/esgo-estro-esp-guidelines-for-the-management-of-patients-with-endometrial/)
- [Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer](https://scholariq.org/papers/minimally-invasive-versus-abdominal-radical-hysterectomy-for-cervical-cancer/)
- [Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update](https://scholariq.org/papers/human-papillomavirus-type-distribution-in-invasive-cervical-cancer-and-high/)
- [Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial](https://scholariq.org/papers/prophylactic-quadrivalent-human-papillomavirus-types-6-11-16-and-18-l1-virus/)
- [Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis](https://scholariq.org/papers/human-papillomavirus-types-in-invasive-cervical-cancer-worldwide-a-meta-analysis/)
- [Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative](https://scholariq.org/papers/global-estimates-of-incidence-and-mortality-of-cervical-cancer-in-2020-a/)
- [Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial](https://scholariq.org/papers/systematic-pelvic-lymphadenectomy-vs-no-lymphadenectomy-in-early-stage/)
- [Endometrial cancer](https://scholariq.org/papers/endometrial-cancer/)
- [Rethinking ovarian cancer: recommendations for improving outcomes](https://scholariq.org/papers/rethinking-ovarian-cancer-recommendations-for-improving-outcomes/)
- [Improved Survival with Bevacizumab in Advanced Cervical Cancer](https://scholariq.org/papers/improved-survival-with-bevacizumab-in-advanced-cervical-cancer/)
- [American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer](https://scholariq.org/papers/american-cancer-society-american-society-for-colposcopy-and-cervical-pathology-3/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer-diagnosis-treatment/)

## Topic primary papers

Showing 15 of 153.

- [Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer](https://scholariq.org/papers/concurrent-cisplatin-based-radiotherapy-and-chemotherapy-for-locally-advanced/)
- [Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix](https://scholariq.org/papers/concurrent-chemotherapy-and-pelvic-radiation-therapy-compared-with-pelvic/)
- [ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma](https://scholariq.org/papers/esgo-estro-esp-guidelines-for-the-management-of-patients-with-endometrial/)
- [Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer](https://scholariq.org/papers/minimally-invasive-versus-abdominal-radical-hysterectomy-for-cervical-cancer/)
- [Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial](https://scholariq.org/papers/systematic-pelvic-lymphadenectomy-vs-no-lymphadenectomy-in-early-stage/)
- [Endometrial cancer](https://scholariq.org/papers/endometrial-cancer/)
- [Improved Survival with Bevacizumab in Advanced Cervical Cancer](https://scholariq.org/papers/improved-survival-with-bevacizumab-in-advanced-cervical-cancer/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer-diagnosis-treatment/)
- [Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial](https://scholariq.org/papers/vaginal-brachytherapy-versus-pelvic-external-beam-radiotherapy-for-patients-with/)
- [Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer](https://scholariq.org/papers/pembrolizumab-for-persistent-recurrent-or-metastatic-cervical-cancer/)
- [Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer](https://scholariq.org/papers/dostarlimab-for-primary-advanced-or-recurrent-endometrial-cancer/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer/)
- [Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-advanced-endometrial-cancer/)
- [Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer](https://scholariq.org/papers/survival-after-minimally-invasive-radical-hysterectomy-for-early-stage-cervical/)
- [Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-iii-trial-of-four-cisplatin-containing-doublet-combinations-in-stage-ivb/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.